| Patient | Duke Kahanamoku |
|---|---|
| Date of birth | 1959-08-24 |
| Identifiers | MRN HR-ML050-SYN; SSN (made up) 000-50-6847 |
| Document date | 2026-09-28 |
| Author | Kawika Lindgren-Morrison, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-month review: repeat echocardiogram and the defibrillator decision. [S]
Mr. Kahanamoku returns two weeks after his annual wellness visit; at his wish, members of his ʻohana joined him for the defibrillator discussion. He completed all 36 sessions of cardiac rehabilitation in the summer, swam in the pool there for the last month, and now swims three mornings a week in calm water inside the reef with a friend; he has not surfed big waves. He has had no swelling, orthopnea, palpitations, lightheadedness or fainting. The planned increase of sacubitril-valsartan two weeks after his last review did not happen: the nurse called, but he put off the laboratory visit twice because of work, the call was not repeated, and he stayed on the starting dose. He takes every dose of his medicines. Today's echocardiogram shows the ejection fraction has risen from 30% to 38%. [S]
| Element | Detail |
|---|---|
| Rehabilitation | All 36 sessions completed |
| Activity | Swims three mornings a week in calm water with a companion |
| Missed step | Sacubitril-valsartan increase and its laboratory check did not happen |
| Echocardiogram | Ejection fraction 38%, from 30% |
| KCCQ-12 | 80, from 38 at intake |
| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No chest pain, palpitations, fainting or ankle swelling |
| Respiratory | Negative | Breathless only swimming hard against a current |
| Neurological | Negative | No lightheadedness |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Aspirin 81 mg delayed-release oral tablet, one tablet daily | One tablet daily | Oral route | 2021-06-21 | active | S |
| Atorvastatin 40 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2021-06-21 to 2026-03-16 | completed | S |
| Atorvastatin 80 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-16 | active | S |
| Metoprolol tartrate 25 mg oral tablet, one tablet twice daily | One tablet twice daily | Oral route | 2021-06-21 to 2026-03-30 | completed | S |
| Lisinopril 10 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2021-06-21 to 2026-03-30 | completed | S |
| Furosemide 40 mg oral tablet, one tablet every morning | One tablet every morning | Oral route | 2026-03-16 to 2026-04-27 | completed | S |
| Furosemide 20 mg oral tablet, one tablet every morning | One tablet every morning | Oral route | 2026-04-27 | active | S |
| Sacubitril 24 mg / valsartan 26 mg oral tablet, one tablet twice daily, first dose 36 hours after the last lisinopril | One tablet twice daily | Oral route | 2026-03-30 to 2026-09-28 | completed | S |
| Sacubitril 49 mg / valsartan 51 mg oral tablet, one tablet twice daily | One tablet twice daily | Oral route | 2026-09-28 | active | S |
| Carvedilol 3.125 mg oral tablet, one tablet twice daily with food, starting the evening after the last metoprolol tartrate | One tablet twice daily with food | Oral route | 2026-03-30 to 2026-04-13 | completed | S |
| Carvedilol 6.25 mg oral tablet, one tablet twice daily with food | One tablet twice daily with food | Oral route | 2026-04-13 to 2026-04-27 | completed | S |
| Carvedilol 12.5 mg oral tablet, one tablet twice daily with food | One tablet twice daily with food | Oral route | 2026-04-27 | active | S |
| Empagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating or drinking | One tablet daily, with sick-day rules | Oral route | 2026-03-30 | active | S |
| Spironolactone 25 mg oral tablet, one-half tablet (12.5 mg) daily | One-half tablet daily | Oral route | 2026-04-13 | active | S |
| Ferric carboxymaltose 750 mg (15 mL vial, 50 mg/mL) by intravenous infusion, two doses two weeks apart | Two infusions two weeks apart | Intravenous route | 2026-03-30 to 2026-04-13 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-09-28 | Body height | 185 | cm | S |
| 2026-09-28 | Body weight | 92.8 | kg | S |
| 2026-09-28 | Body mass index (BMI) [Ratio] | 27.1 | kg/m2 | S |
| 2026-09-28 | Systolic blood pressure | 106 | mm[Hg] | S |
| 2026-09-28 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 2026-09-28 | Heart rate | 64 | /min | S |
| 2026-09-28 | Respiratory rate | 16 | /min | S |
| 2026-09-28 | Body temperature | 36.5 | Cel | S |
| 2026-09-28 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-09-28 | Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma | 620 | pg/mL | Below 125 pg/mL makes heart failure unlikely outside the hospital | High | S |
| 2026-09-28 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-09-28 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-09-28 | Creatinine [Mass/volume] in Serum or Plasma | 1.14 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-09-28 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 70 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-09-28 | Glucose [Mass/volume] in Serum or Plasma | 95 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-09-28 | Magnesium [Mass/volume] in Serum or Plasma | 2 | mg/dL | 1.6-2.6 mg/dL | Normal | S |
| 2026-09-28 | Hemoglobin [Mass/volume] in Blood | 14.1 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2026-09-28 | Ferritin [Mass/volume] in Serum or Plasma | 248 | ng/mL | In heart failure, below 100 ng/mL, or 100 to 299 with transferrin saturation below 20%, is iron deficiency | Normal | S |
| 2026-09-28 | Iron saturation [Mass Fraction] in Serum or Plasma | 27 | % | 20-50% | Normal | S |
| 2026-09-28 | Left ventricular Ejection fraction | 38 | % | 50-70% | Low | S |
| 2026-09-28 | Overall summary score [KCCQ-12] | 80 | {score} | S |
Vital signs recorded on 2026-09-28; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 106/66, pulse 64; weight 92.8 kg |
| Orthostatic vital signs | Standing at three minutes 104/64 mmHg without symptoms |
| Neck | Jugular venous pressure not raised |
| Cardiovascular | Regular rhythm; soft apical systolic murmur; no S3 |
| Respiratory | Clear |
| Extremities | No edema |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Breathlessness on exertion for six weeks (paddling out, walking uphill, finishing his morning swim), with ankle swelling by evening and tiredness, five years after a heart attack; cause to be determined | resolved | confirmed | R06.09 | S — Synthetic presenting problem, resolved at the second visit when the echocardiogram and cardiology established heart failure with reduced ejection fraction. |
| Coronary artery disease with an old anterior myocardial infarction five years ago, treated with medicines; synthetic modern episode linked to the documented heart attack of 1952 | active | confirmed | I25.2 | S — Synthetic modern diagnosis; the 1952 heart attack remains D in the history. |
| Heart failure with reduced ejection fraction from ischemic cardiomyopathy (ejection fraction 30% with a thinned, akinetic anterior wall and apex), NYHA class III at diagnosis | active | confirmed | I50.22 | S — Synthetic modern diagnosis made at the second visit; no claim that he had heart failure in his lifetime. |
| Iron deficiency without anemia (ferritin 62 ng/mL, transferrin saturation 16%) | active | confirmed | E61.1 | S — Synthetic finding at the heart failure workup. |
| Viral gastroenteritis for two days, with volume depletion, potassium 5.5 mmol/L and a rise in creatinine on sacubitril-valsartan, spironolactone, empagliflozin and furosemide; settled with sick-day rules | resolved | confirmed | A08.4 | S — Synthetic intercurrent problem at an unscheduled visit; it follows from his heart failure medicines and does not echo a documented illness. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure and heart rate (seated and standing) | Every visit | Completed today | 106/66 mmHg, pulse 64; standing 104/64 without symptoms |
| Examination | Weight, volume status (jugular venous pressure, edema, lungs) and NYHA class | Every visit | Completed today | 92.8 kg; jugular venous pressure not raised; no edema; NYHA I to II |
| Laboratory | Metabolic panel (sodium, potassium, creatinine and eGFR) and magnesium | One to two weeks after a dose change | Deferred | The panel due one week after the planned sacubitril-valsartan increase was never drawn, because the increase itself did not happen: he put off the laboratory visit twice for work and the nurse's call was not repeated. No laboratory harm resulted (potassium 4.6, creatinine 1.14 today), but the ARNI stayed at the starting dose for about five months, which may have limited his recovery. Corrective action: laboratory tests drawn at the clinic on the day of each change or by the nurse at home, and nurse calls that continue until each step is done |
| Laboratory | Metabolic panel (sodium, potassium, creatinine and eGFR) and magnesium | Every three to six months when stable | Completed today | Sodium 138, potassium 4.6, creatinine 1.14 mg/dL (eGFR 70), magnesium 2.0 |
| Medication safety | Guideline-directed medical therapy: ARNI, evidence-based beta-blocker, MRA and SGLT2 inhibitor, toward target doses | Every two weeks during titration | Completed today | Sacubitril-valsartan raised to 49/51 mg today; panel in one to two weeks |
| Imaging | Echocardiogram | At diagnosis; repeat after three to six months of optimized therapy for device decisions, or with unexplained change | Completed today | After more than 90 days of therapy: ejection fraction 38% (from 30%), end-diastolic diameter 58 mm, mild mitral regurgitation |
| Examination | Primary-prevention ICD evaluation (and CRT if QRS is wide) | After at least 90 days of optimized therapy, and at least 40 days after a myocardial infarction | Not indicated | Ejection fraction 38%, above 35%; QRS 104 ms; no ICD or CRT now |
| Laboratory | NT-proBNP | At diagnosis; selectively for prognosis (not for titration) | Completed today | 620 pg/mL, from 2,450, for prognosis |
| Medication safety | Iron studies (ferritin, transferrin saturation) and intravenous iron | At diagnosis; after repletion and about yearly | Completed today | Ferritin 248 ng/mL, transferrin saturation 27%, hemoglobin 14.1 g/dL |
| Survey | KCCQ-12 heart failure health status | At diagnosis, then every three to six months | Completed today | 80 |
| Laboratory | Lipid panel | Every three to twelve months when stable | Up to date | LDL 62 mg/dL in the spring |
| Survey | Depression screen (PHQ-2, then PHQ-9 if positive) | Periodically | Up to date | PHQ-2 0 at the wellness visit |
| Referral | Cardiac rehabilitation for heart failure | When eligible: ejection fraction 35% or below, NYHA II to IV, six weeks of stable therapy and no procedure in six weeks | Completed today | All 36 sessions completed in the summer; swimming in calm water with a companion |
| Examination | Vaccinations (pneumococcal, influenza, COVID-19, RSV) | Yearly or per schedule | Completed today | Influenza, RSV and COVID-19 at the wellness visit; PCV20 in the spring; zoster dose 1 and Tdap today |
| Self-management | Self-care: daily weights, sodium, sick-day rules and symptoms to report | Every visit | Completed today | Daily weights; ocean plan followed; sick-day card kept in his wallet |
| Self-management | Culturally safe care: ʻohana involvement as he chooses; his own healing practices | Every visit | Completed today | ʻOhana included in the defibrillator discussion, as he asked at the wellness visit |
Goal progress:
Immunizations given today: Recombinant zoster vaccine, dose 1 of 2; Tetanus, diphtheria, and acellular pertussis vaccine (Tdap) [S]
Guideline basis: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction (2024); 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (2017); CMID: Clinical Monitoring Intelligence Database, heart failure and ischemic heart disease monographs (2026); Adult Immunization Schedule by Age (2026)
Follow-up: Zoster dose 1 and Tdap given today; second zoster dose in two to six months. Metabolic panel at the clinic in one to two weeks, with the nurse's call. Review in three months. Cardiology review in six months. Call 911 for chest pain, fainting or a racing heartbeat. [S]